AASLD's The Liver Meeting 2021 Investor Hub
- BPIQ
- Sep 29, 2021
- 4 min read
Summary
The Liver Meeting is a yearly conference that is the premier meeting on liver disease and cutting-edge science
This meeting occurs from November 12-15, 2021 and is a completely remote conference as in 2020
Abstracts will be released in early October, at which time stocks may drastically change because of the embargo policy being lifted
See our full AASLD 2021 Investor forum post HERE for additional information on companies and assets after signing up. Learn more here.
Want to get Catalyst Events and stocks to watch sent directly to your inbox each week? sign up for our free weekly newsletter
The American Association for the Study of Liver Diseases (AASLD) holds multiple events and conferences every year, including The Liver Meeting every fall. This year The Liver Meeting starts November 12, 2021 and extends through November 15, 2021. As in 2020, The Liver Meeting is a 100% digital experience this year. Earlier this summer the board posted a notice that they would be canceling the in-person component of The Liver Meeting which was supposed to be held in Anaheim, making The Liver Meeting a completely digital experience. https://www.aasld.org/the-liver-meeting/important-message-governing-board.
The AASLD Liver Meeting is the “world’s premier meeting on liver disease” and features cutting edge science in the field. https://www.aasld.org/the-liver-meeting. In 2019 The Liver Meeting was hosted in Boston, Massachusetts but moved to a digital experience in 2020 because of the COVID-19 pandemic. The digital experience allows participants to have access to all programs until February 15, 2022 which includes ePosters, live educational content, virtual exhibit hall, networking, and much more. https://www.aasld.org/the-liver-meeting/program/digital-experience.
Abstracts were submitted from April 1 to June 18, 2021 and companies were notified of selection on August 16, 2021. Late breaking abstracts were submitted from September 8 to September 15, 2021 and companies will be notified of selection in early October. To learn more about the embargo policy for The Liver Meeting read our full forum post HERE.
Every year, upon abstract release and as a result of presentations at the conference, some biopharma stocks move significantly because they report important clinical trial updates. As experienced biopharma investors understand, the value of a biopharma company is based in large part on the value of its clinical assets. This value takes into account the likelihood of success of the clinical assets of the underlying company in successfully completing clinical trials. An update to a clinical trial that shows some positive results in safety and especially efficacy, can increase the chance of success for that trial, which increases the value of the asset and the underlying company. The converse is true as well, for disappointing results.
Positive clinical trial results in a single trial can have a significant impact on the underlying stock price. This is especially true for biopharma companies with market caps under $5 billion, who typically have far less clinical and approved assets than larger companies, and thus whose valuation can be more affected by a single drug candidate and trial. The clinical assets of these micro, small and mid-cap cancer biopharma companies are a primary driver for the development of future cancer therapies.
With respect to The Liver Meeting 2021 and biomedical conferences in general, a big challenge for investors is to identify in advance, companies that are reporting significant clinical trial updates at the conference. Many presentations provide less significant information with respect to company valuation (e.g. preclinical results or clinical trial design). At BiopharmIQ (BPIQ.com; "BPIQ") we oversee a database of information about clinical assets and their upcoming clinical trial and other catalyst events for virtually every biopharma company with a market cap of between $100M and $5B, which for convenience in this article, we will refer to as smid-cap biopharma companies. Currently, our database has over 500 smid-cap biopharma companies. Our goal at BPIQ is to provide information and education on smid-CAP biopharma companies to level the playing field for all investors, whether retail, professional or institutional.
To this end, our team updated and scoured through our BPIQ database to identify biopharma companies that are presenting clinical trial updates at The Liver Meeting 2021. Table 1 (provided at the end of this article) lists those companies in our BPIQ database that are presenting clinical update(s) at The Liver Meeting. Table 1 provides the drug candidate name, indication, and clinical phase. To see more information about these trials including data expected at The Liver Meeting and investor calls visit our full forum article HERE after signing up. Learn more here.
The question for biopharma investors now with respect to the actual AASLD The Liver Meeting 2021 digital experience being held November 12-15 is which stocks or groups of stocks are likely to move upon the release of the abstracts, posters, or associated investor meeting. We plan to update information about the presentations on BPIQ.com in the forum article as they become available. In the meantime, the information provided in this article provides an interesting snapshot into the smid-cap biopharma companies that are developing some of the leading medicines for NASH and other liver diseases. For investors, these companies represent an exciting opportunity for further diligence and possible investment.
Table 1. BPIQ.com smid-cap companies presenting at AASLD’s The Liver Meeting 2021
If you are serious about investing in biotech stocks BPIQ is the research companion that will take you to the next level.
Save yourself time by accessing our database of over 550 companies, 1,800+ of their drug assets, and tools including: Catalyst Calendar, Big Movers, Company Pipelines, and more!
P.S. We are currently running a sale - lock in the price before it's gone
See what our members are saying about us:
Mike from United States
“Really loving the site over the competitor... like the layout and speed over the competition...like the individual pages for each drug/treatment”
Carl from United States
“I like your service. I haven’t seen anyone else doing something similar...nothing like this available for retail.”
Essey from Canada
“Love what you’re doing, this website is awesome.”
James from United States
Great site and I see it’s a family run business, great job.”
Comments